Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein as Chief Medical Officer
July 18, 2019 at 06:30 am EDT
Iovance Biotherapeutics, Inc. announced the appointment of Friedrich Graf Finckenstein, M.D., as chief medical officer. Prior to joining Iovance he was Global Head of Oncology Translational Medicine at Roche Pharma Research and Early Development (pRED) in Basel, Switzerland, where he led all clinical development aspects in the Oncology Discovery and Translational Area, including the design and conduct of clinical trials, exploratory development studies and translational medicine, biomarker and personalized healthcare strategy.